Vera Therapeutics, Inc.
NASDAQ:VERABiotechnology
+$0.09 today
- Market cap
- $1.85B
- Beta
- 0.95
- P/E (TTM)
- -6.8
- EPS (TTM)
- -$5.16
Volume 0.95M
Average 1.18M
VERA Gross Margin
Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.
Gross Margin history
Percent of revenue · from the income statement
No Gross Margin data reported for this period type.
Gross Margin vs competitors
How VERA compares with its peers on the latest reported figures
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Mar 2026 | 116.4% | +166.6 pp | +862.2 pp | |
| LTM Jun 2026 | 96.0% | -4.0 pp | +0.0 pp | |
| LTM Jun 2026 | 91.1% | +2.0 pp | +10.7 pp | |
ALMSAlumis Inc. Common Stock | LTM Jun 2026 | 88.2% | -7.7 pp | — |
| LTM Mar 2026 | 87.3% | -1.7 pp | -3.6 pp | |
| LTM Mar 2026 | 76.3% | +55.8 pp | +13.5 pp | |
| FY2025 | — | — | — | |
| FY2025 | — | — | — | |
| FY2025 | — | — | — | |
| FY2025 | — | — | — | |
| Peer median (excluding VERA) | 89.7% | +0.2 pp | +10.7 pp | |
Competitors are the stored peer set for VERA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | (846K) | 0 | 0 | 0 |
| Gross Profit | 0 | 846K | 0 | 0 | 0 |
| Gross Margin | — | — | — | — | — |
| Research & Development | 22.48M | 69.84M | 78.23M | 126.17M | 215.26M |
| Selling, General & Admin | 11.92M | 21.91M | 23.79M | 41M | 100.22M |
| Operating Expenses | 34.4M | 91.75M | 102.01M | 167.17M | 315.47M |
| Depreciation & Amortization | 176K | (846K) | 21K | 105K | 468K |
| EBITDA | (32.41M) | (88.91M) | (92.18M) | (144.42M) | (291.62M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (34.4M) | (90.9M) | (102.01M) | (167.17M) | (315.47M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 15K | 1.75M | 7.98M | 20.71M | 24.48M |
| Interest Expense | 20K | 992K | 3.79M | 7.63M | 7.53M |
| Other Income / Expenses | 1.79M | 1.85M | 6.02M | 15.02M | 15.86M |
| Income Before Tax | (32.61M) | (89.06M) | (95.99M) | (152.15M) | (299.61M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 1K | 1K | 1K | 1K | 1K |
| Net Income | (32.61M) | (89.06M) | (95.99M) | (152.15M) | (299.62M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (2.43) | (3.35) | (2.25) | (2.75) | (4.66) |
| EPS (Diluted) | (2.43) | (3.35) | (2.25) | (2.75) | (4.66) |
| Weighted Avg Shares | 13.44M | 26.57M | 42.71M | 55.33M | 64.23M |
| Weighted Avg Shares (Diluted) | 13.44M | 26.57M | 42.71M | 55.33M | 64.23M |
Vera Therapeutics, Inc.
NASDAQ:VERA
Intrinsic Alpha fair value
Locked
Current Price
$25.58
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.